Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-08-18

FDA Approved: FLUOXETINE — Supplemental Application (ScieGen Pharmaceuticals, Inc)

View source ↗

Summary

FDA approved a supplemental application for a ScieGen Pharmaceuticals generic fluoxetine product under anANDA process.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Fluoxetine (Fluoxetine)

Snippet

SUPPL AP for FLUOXETINE (FLUOXETINE)